Common wart

Summary

Common wart (MONDO:0001209) is a disease with 11 GWAS associations across 15 studies and 36 clinical trials. Top therapeutic interventions include hydrogen peroxide, methylene blue cation, and cantharidin. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 11
• Clinical trials: 36

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	common wart
Mondo ID	MONDO:0001209
EFO	EFO:0009662
MeSH	D014860
DOID	DOID:11165
ICD-10-CM	B07
ICD-11	1074706780
NCIT	C27087
SNOMED CT	57019003
UMLS	C3665596
MedGen	777120
Is cancer (heuristic)	no

Also known as: common wart · verruca vulgaris

Data availability: 11 GWAS associations (15 studies).

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › common wart

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Genetics & variants

GWAS landscape

11 GWAS associations across 15 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs28383322	4e-86	HLA-DRB1 - HLA-DQA1	C	0.24
chr6:32632785	2e-50		T	0.17
rs12203592	1e-12	IRF4	C	0.1
chr6:32632080	1e-11		C	0.21
chr6:9583318	1e-08		T	2.02
chr12:130610551	1e-08		C	2.75
chr19:9500514	4e-08		T	1.49
chr8:21724740	4e-08		A	2.73
chr5:1292868	5e-08		A	0.06
rs7210800	3e-07	RPL39P33 - NOG	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475555	Verma A	2024	21,895	403,003	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473054	UK Biobank Whole-Genome Sequencing Consortium	2025	16,605	441,835	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667826	UK Biobank Whole-Genome Sequencing Consortium	2025	16,605	441,835	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90103384	Fitzgerald T	2022	6,519	164,238	CNest: A novel copy number association discovery method uncovers 862 new associations from 200,629 whole-exome sequence datasets in the UK Biobank.
GCST90726647	Kim HI	2026	4,967	39,059	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90079550	Backman JD	2021	4,761	372,404	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083536	Backman JD	2021	4,761	372,404	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90475554	Verma A	2024	4,166	113,429	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479754	Verma A	2024	4,166	113,429	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477064	Verma A	2024	2,723	54,524	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	10

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	6

Functional consequences

Consequence	Count
unknown	7
intergenic_variant	2
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs28383322	6	32625019	C>A,T	0.231	intergenic_variant	HLA-DRB1 - HLA-DQA1	4e-86	Tier 4: intronic/intergenic
chr6:32632785							2e-50	Tier 4: intronic/intergenic
rs12203592	6	396321	C>G,T	0.128	intron_variant	IRF4	1e-12	Tier 4: intronic/intergenic
chr6:32632080				0.499			1e-11	Tier 4: intronic/intergenic
chr6:9583318							1e-08	Tier 4: intronic/intergenic
chr12:130610551							1e-08	Tier 4: intronic/intergenic
chr19:9500514							4e-08	Tier 4: intronic/intergenic
chr8:21724740							4e-08	Tier 4: intronic/intergenic
chr5:1292868							5e-08	Tier 4: intronic/intergenic
rs7210800	17	56573285	C>A,G	0.05	intergenic_variant	RPL39P33 - NOG	3e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Salicylic Acid	Approved (phase 4)
Furosemide	Phase 3 (in late-stage trials)
Hydrogen Peroxide	Phase 3 (in late-stage trials)
Tuberculin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 36.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	13
PHASE2	11
PHASE3	7
PHASE4	4
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03977753	PHASE4	RECRUITING	Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
NCT07448844	PHASE4	RECRUITING	Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
NCT03183765	PHASE4	COMPLETED	Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts
NCT05070754	PHASE4	COMPLETED	Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
NCT07246590	PHASE3	RECRUITING	Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07457918	PHASE3	RECRUITING	Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT03687372	PHASE3	COMPLETED	Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03691831	PHASE3	COMPLETED	A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510	PHASE3	COMPLETED	Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT04288817	PHASE3	UNKNOWN	Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
NCT05937672	PHASE3	TERMINATED	Cold Atmospheric Plasma Device Extension Study
NCT01286441	PHASE2	COMPLETED	A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
NCT01796795	PHASE2	SUSPENDED	Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
NCT02483455	PHASE2	COMPLETED	ALC-919 For The Treatment Of Common Warts
NCT02640820	PHASE2	UNKNOWN	Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
NCT02669862	PHASE2	COMPLETED	A Study of A-101 Solution in Subjects With Common Warts.
NCT02798419	PHASE2	COMPLETED	Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
NCT03210337	PHASE2	COMPLETED	A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03278028	PHASE2	COMPLETED	A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT03487549	PHASE2	COMPLETED	Cantharidin and Occlusion in Verruca Epithelium
NCT05799157	PHASE2	COMPLETED	Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
NCT05896215	PHASE2	COMPLETED	OM202JP Clinical Study of KNP2002
NCT02748902	PHASE1	COMPLETED	Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
NCT06737406	Not specified	RECRUITING	Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart
NCT06749665	Not specified	NOT_YET_RECRUITING	Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT00328991	Not specified	COMPLETED	Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts
NCT01084824	Not specified	COMPLETED	A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
NCT01609530	Not specified	TERMINATED	Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
NCT02650466	Not specified	COMPLETED	Nanopulse Efficacy Study for the Treatment of Common Warts
NCT03166137	Not specified	UNKNOWN	Carbon Dioxide Laser and Cryotherapy in Treatment of Warts
NCT04620785	Not specified	UNKNOWN	Photodynamic Therapy in Treatment of Verrucae
NCT04793529	Not specified	COMPLETED	Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
NCT05115669	Not specified	COMPLETED	Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts
NCT05409365	Not specified	UNKNOWN	Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
NCT06214559	Not specified	COMPLETED	Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
NCT06958237	Not specified	COMPLETED	Salicylic Acid Wart Patch for the Treatment of Common Warts and Plantar Warts

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HYDROGEN PEROXIDE	4	4
METHYLENE BLUE CATION	4	3
CANTHARIDIN	4	2
ACYCLOVIR	4	1
INGENOL MEBUTATE	4	1
NITROGEN	4	1
VEHICLE	0	5
COLLODION	-1	1